Hudson Bay Capital Management LP Neurocrine Biosciences Inc Transaction History

Hudson Bay Capital Management LP

$24.1 Billion
Q4 2024

A detailed history of Hudson Bay Capital Management LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 30,342 shares of NBIX stock, worth $3.57 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

30,342

Previous 40,000 24.15%

Holding current value

$3.57 Million

Previous $4.61 Million 10.08%

% of portfolio

0.02%

Previous 0.02%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $1.08 Million - $1.35 Million	-9,658 Reduced 24.15%	30,342 $4.14 Million
Q3 2024 Nov 13, 2024	SELL	$114.58 - $153.15 $572,900 - $765,750	-5,000 Reduced 11.11%	40,000 $4.61 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $1.96 Million - $2.15 Million	15,000 Added 50.0%	45,000 $6.2 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $3.59 Million - $3.95 Million	-27,500 Reduced 47.83%	30,000 $4.14 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $795,525 - $995,699	7,500 Added 15.0%	57,500 $7.58 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $2.59 Million - $3.22 Million	-27,500 Reduced 35.48%	50,000 $5.63 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $4.25 Million - $4.98 Million	47,500 Added 158.33%	77,500 $7.31 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $1.8 Million - $2.36 Million	19,160 Added 176.75%	30,000 $3.04 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $10 Million - $12 Million	-94,160 Reduced 89.68%	10,840 $1.29 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $5.98 Million - $7.01 Million	-65,000 Reduced 38.24%	105,000 $11.2 Million
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $1.14 Million - $1.5 Million	15,000 Added 9.68%	170,000 $16.6 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $1.45 Million - $1.9 Million	20,000 Added 14.81%	155,000 $14.5 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $4.39 Million - $5.85 Million	55,111 Added 68.98%	135,000 $11.5 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $852,234 - $979,307	9,889 Added 14.13%	79,889 $7.66 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $447,150 - $511,350	5,000 Added 7.69%	70,000 $6.81 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $437,849 - $597,000	-5,000 Reduced 7.14%	65,000 $6.32 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $3.48 Million - $4.33 Million	40,000 Added 133.33%	70,000 $6.71 Million
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $2.88 Million - $4.05 Million	30,000 New	30,000 $2.89 Million
Q2 2020 Aug 12, 2020	SELL	$85.09 - $130.36 $850,900 - $1.3 Million	-10,000 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $751,100 - $1.14 Million	10,000 New	10,000 $866,000
Q3 2019 Nov 13, 2019	SELL	$83.82 - $101.5 $2.51 Million - $3.05 Million	-30,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $1.81 Million - $2.28 Million	25,000 Added 500.0%	30,000 $2.53 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $346,550 - $457,650	5,000 New	5,000 $441,000

Others Institutions Holding NBIX

# of Institutions

655

Shares Held

96.5M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Account

Hudson Bay Capital Management LP Neurocrine Biosciences Inc Transaction History